ChemioCare Inc., a pharmaceutical company working on a proprietary transdermal delivery platform, has closed a private round of financing, raising $★Research Note – Subscriber ONLY content: read our research and get insight on this and other deals. We offer monthly or yearly recurring or one-time trial subscriptions. Subscribe today and see what you have been missing! ★
ChemioCare’s Vision is to transform current treatment of chemotherapy-induced nausea and vomiting through patch technology.
New York City and Vancouver based based ChemioCare is a newly formed BC company.
photo credit: ChemioCare
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Link Global Technologies files for $1.5M IPO on CSE - January 17, 2019
- Altas Partners sells NSC Minerals to PE-backed Kissner Group - January 17, 2019
- K1 Investment’s PerfectServ acquires Telmediq - January 17, 2019